Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Eiger Biopharma (EIGR)

Eiger Biopharma (EIGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,607
  • Shares Outstanding, K 44,074
  • Annual Sales, $ 12,140 K
  • Annual Income, $ -33,920 K
  • 60-Month Beta 1.93
  • Price/Sales 5.64
  • Price/Cash Flow N/A
  • Price/Book 1.27
Trade EIGR with:

Options Overview Details

View History
  • Implied Volatility 114.49% ( -49.95%)
  • Historical Volatility 111.60%
  • IV Percentile 51%
  • IV Rank 10.92%
  • IV High 747.14% on 01/04/23
  • IV Low 36.89% on 03/01/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 63
  • Volume Avg (30-Day) 72
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 3,073
  • Open Int (30-Day) 4,516

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.53
  • Number of Estimates 1
  • High Estimate -0.53
  • Low Estimate -0.53
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +17.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.18 +72.88%
on 01/09/23
2.27 -10.13%
on 02/07/23
+0.84 (+70.00%)
since 01/06/23
3-Month
0.96 +112.50%
on 12/08/22
4.69 -56.50%
on 11/14/22
-2.00 (-49.50%)
since 11/08/22
52-Week
0.96 +112.50%
on 12/08/22
10.02 -79.64%
on 03/23/22
-2.39 (-53.95%)
since 02/08/22

Most Recent Stories

More News
New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

/PRNewswire/ -- Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 2.04 (-9.73%)
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger...

EIGR : 2.04 (-9.73%)
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Notifies Eiger BioPharmaceuticals, Inc. (EIGR) Investors of Class Action and Encourages Investors to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) (NASDAQ:...

EIGR : 2.04 (-9.73%)
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Eiger Investors of a Lead Plaintiff Deadline of January 9, 2023

/PRNewswire/ -- Attention Eiger BioPharmaceuticals, Inc. ("Eiger") (NASDAQ: EIGR) shareholders: The Law Offices of Vincent Wong announce that a class action...

EIGR : 2.04 (-9.73%)
EIGER DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Eiger Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Eiger Biopharmaceuticals, Inc. (“Eiger” or the...

EIGR : 2.04 (-9.73%)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)

The Law Offices of Frank R. Cruz reminds investors of the upcoming January 9, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Eiger BioPharmaceuticals,...

EIGR : 2.04 (-9.73%)
EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023

/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Eiger BioPharmaceuticals, Inc....

EIGR : 2.04 (-9.73%)
EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action...

EIGR : 2.04 (-9.73%)
EIGER BIOPHARMACEUTICALS, INC. (NASDAQ: EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ:

/PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a...

EIGR : 2.04 (-9.73%)
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - EIGR

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)...

EIGR : 2.04 (-9.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.

See More

Key Turning Points

3rd Resistance Point 2.42
2nd Resistance Point 2.33
1st Resistance Point 2.19
Last Price 2.04
1st Support Level 1.96
2nd Support Level 1.87
3rd Support Level 1.73

See More

52-Week High 10.02
Fibonacci 61.8% 6.56
Fibonacci 50% 5.49
Fibonacci 38.2% 4.42
Last Price 2.04
52-Week Low 0.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar